Results of adjuvant radiation therapy for locoregional perihilar cholangiocarcinoma after curative intent resection
Authors Leng KM, Liu YP, Wang ZD, Zhong XY, Liao GQ, Kang PC, Cui YF, Jiang XM
Received 7 January 2017
Accepted for publication 13 March 2017
Published 21 April 2017 Volume 2017:10 Pages 2257—2266
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Lucy Goodman
Peer reviewer comments 3
Editor who approved publication: Dr Chiung-Kuei Huang
Kai-Ming Leng,1,* Yue-Ping Liu,1,* Zhi-Dong Wang,1 Xiang-Yu Zhong,1 Guan-Qun Liao,2 Peng-Cheng Kang,1 Yun-Fu Cui,1 Xing-Ming Jiang1
1Department of Hepatopancreatobiliary Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, 2Department of General Surgery, Foshan Hospital Affiliated to Southern Medical University, Foshan, People’s Republic of China
*These authors contributed equally to this work
Purpose: This study sought to define the role of adjuvant radiation therapy (RT) for patients with curative intent resection of perihilar cholangiocarcinoma (pCCA).
Patients and methods: By using the Surveillance, Epidemiology and End Results (SEER) registry, 1,917 patients with non-metastatic pCCA who underwent surgical resection from 1988 to 2009 were included in this study. Propensity score methods were used to compare the survival outcomes of patients treated with and without adjuvant RT after controlling for selection bias.
Results: Of the 1,917 patients, 762 (39.7%) received adjuvant RT. In the unmatched population, median overall survival (OS) for patients receiving adjuvant RT compared with those undergoing surgery alone was 23 versus 22 months (P=0.651). Patients who received adjuvant RT were younger (65 vs 68 years, P<0.001), had more regional diseases (86.0% vs 76.7%, P<0.001), and had more positive lymph nodes (43.8% vs 32.2%, P<0.001). In the matched population, adjuvant RT did not show better OS (22 vs 23 months, P=0.978) or cancer-specific survival (CSS) (17 vs 18 months, P=0.554).
Conclusion: Adjuvant RT is not associated with improved survival of patients with resected pCCA. These data suggest that adjuvant RT should not be routinely used to treat patients with pCCA outside research trials. Ideally, prospective randomized trials should be performed to verify the conclusion of this study.
Keywords: perihilar cholangiocarcinoma, radiation therapy, SEER, propensity score, survival, surgery
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]